 |
|
|
|
November 2000 Cover
|
|
Abbott Laboratories obtained a surprising early approval from the Food and Drug Administration for its
new protease inhibitor AIDS medicine, Kaletra, which reduced HIV in the bloodstream to undetectable levels for
the majority of patients taking the drug during clinical trials. Kaletra is, in fact, a blend of two AIDS
medicines, lopinavir, or ABT-378, and ritonavir, which is currently available under the brand name of Norvir. The
combination drug lowered signs of HIV to below detectable levels in 83 of 100 patients after nearly two years in
the study.
Editor's Note: from The Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
